Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Next Previous
X
Search
Trial Profile

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma Global Development

    • Most Recent Events

    • 09 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.
    • 06 Jun 2023 Interim results (n=6; As of data cutoff 1 Dec 2022) assessing the safety, PK, and efficacy data for 125mg and 250mg doses of intravesical enfortumab vedotin in patients with non-muscle invasive bladder cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Apr 2023 According to Seagen media release, an abstract (Abstract NO. 4596) including an interim results from this study will be present at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023, in Chicago.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top